HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors-Reference-Cited by-同舟云学术

HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors

Published:2022-08 Issue: Volume:170 Page:1-10
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Cuppens Kristof,Baas Paul,Geerdens Ellen,Cruys Bert,Froyen Guy,Decoster Lynn,Thomeer Michiel,Maes Brigitte

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference51 articles.

1. R.L. Siegel, K.D. Miller, A. Jemal, Cancer Statistics, 2017, CA: a cancer journal for clinicians 67

2. (1) (2017) 7-30. https://doi.org/10.3322/caac.21387.

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

4. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl. J. Med.,2014

5. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer;Soria;N Engl. J. Med.,2018

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion;Biology;2024-04-28

2. HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer;Lung Cancer;2024-03

3. Metrics and their misapplications Audit Culture: How Indicators and Rankings Are Reshaping the World Cris Shore and Susan Wright Pluto Press, 2024. 256 pp.;Science;2024-02-23

4. An immunogenetic basis for lung cancer risk;Science;2024-02-23

5. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative;Journal for ImmunoTherapy of Cancer;2024-02